News

On June 11, 2024, the Court in Case No. 1:22-cv-00061 (N.D.W. Va.) / MDL 1:24-md-03103 (N.D.W. Va.) issued a permanent injunction against the launch of Biocon and Mylan’s Yesafili™ (aflibercept-jbvf), a recently approved interchangeable biosimilar of Regeneron’s EYLEA® (aflibercept) (previously reported FDA Approves First Two Interchangeable EYLEA® Biosimilars – Biocon’s Yesafili™ (aflibercept-jbvf) and Samsung Bioepis’s Opuviz™ (aflibercept-yszy)).  The permanent injunction comes after the Court’s finding in December 2023 that Yesafili™ infringed method of treatment claims 4, 7, 9, 11, 14-17 of Regeneron’s U.S. Patent No. 11,084,865 (previously reported EYLEA® (aflibercept) and Soliris® (eculizumab) IPR and BPCIA Litigation Updates).  In the December 2023 order, the Court also found Yesafili™ infringed claims 6 and 25 of U.S. Patent No. 11,253,572 and claims 11 and 19 of U.S. Patent No. 10,888,601, but found those claims invalid.  In March 2024, the Court granted summary judgment of noninfringement due to disclaimer of U.S. Patent Nos. 10,406,226, 10,464,992, and 10,857,205.  The case remains pending as to 18 additional asserted patents.

Numerous other EYLEA® biosimilars are currently involved in litigations, including Samsung Bioepis’s Opuviz™ (aflibercept-yszy) (FDA-approved May 20, 2024), Formycon’s FYB203 (aBLA accepted by FDA in August 2023), Celltrion’s CT-P42 (aBLA submitted to FDA in June 2023), and Amgen’s ABP 938 (aBLA accepted by FDA in October 2023).  Preliminary injunctions are pending in each of these cases, and the launch of Opuviz™ is under a Temporary Restraining Order through June 14, 2024.

We continue to monitor these cases and will provide updates as they become available. For more information about these and other biosimilar patent disputes, please visit BiologicsHQ.

 

_____________________________________________________

The author would like to thank April Breyer Menon for her contributions to this article.


    Methodology

    Information contained in the Venable BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable BiologicsHQ database.

    Disclaimer

    The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

    Subscribe for Future Updates

      captcha